Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 14/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222568 | 0.93 | LMNA (0.54) | ALDH1A1CXCR4HRH3LMNASIGMAR1 | |
| SCHEMBL27416833 | 0.92 | LMNA (0.55) | ALDH1A1HRH3LMNASIGMAR1KDM5C | |
| Hydrochloric Acid SCHEMBL6141847 | 0.90 | LMNA (0.58) | ALDH1A1MEN1CHRM2CHRM1KMT2A | |
| SCHEMBL7433040 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ALMNABRD4 | |
| SCHEMBL21044029 | 0.84 | ALDH1A1 (0.48) | ALDH1A1LMNASIGMAR1KDM5CKDM4C | |
| SCHEMBL17929342 | 0.83 | CXCR4 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL11361974 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ALMNABRD4 | |
| SCHEMBL6842740 | 0.79 | LMNA (0.54) | ALDH1A1HRH3LMNASIGMAR1BRD4 | |
| SCHEMBL15966079 | 0.77 | LMNA (0.59) | ALDH1A1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL26682722 | 0.77 | MPO (0.66) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088134-A1 | NOVEL BORONSOME FACILITATING DIAGNOSIS AND TREATMENT | 北京大学 | 2023-05-25 | — | — | WO | disclosed |
| US-11591402-B2 | Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210277125-A1 | ANTIBODIES THAT BIND INTEGRIN AVB8 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-09 | — | — | US | disclosed |
| US-20210230279-A1 | NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY | UNIV CALIFORNIA (US) | 2021-07-29 | — | — | US | disclosed |
| US-10954304-B2 | Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200338211-A1 | METHOD OF TREATMENT FOR SOLID TUMORS CONTAINING HYPOXIA AND/OR STROMA FEATURES | WAYNE STATE UNIVERSITY (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190218298-A1 | NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| US-9845357-B2 | Integrin αvβ8 neutralizing antibody | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-19 | — | — | US | disclosed |
| US-9370489-B2 | Combinational liposome compositions for cancer therapy | MALLINCKRODT LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160137737-A1 | INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-05-19 | — | — | US | disclosed |
| US-20140234217-A1 | REMOTE ASSEMBLY OF TARGETED NANOPARTICLES USING COMPLEMENTARY OLIGONUCLEOTIDE LINKERS | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2014-08-21 | — | — | US | disclosed |
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130121917-A1 | Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof | LAWRENCE BERKELEY NATIONAL LABORATORY (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115273-A1 | Combinational Liposome Compositions for Cancer Therapy | MALLINCKRODT LLC (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130064837-A1 | INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | MALLINCKRODT LLC (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110027172-A1 | DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-03 | — | — | US | disclosed |
| WO-2009110939-A9 | DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009110939-A2 | DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-11 | — | — | WO | disclosed |
| US-6395255-B1 | ANALOG INCLUDES RADIOLABELING MOIETY OF FOUR AMINO ACIDS WHICH COMPLEX WITH SELECTED RADIONUCLEOTIDE, 4-AMINOBUTYRIC ACID, AND A SPECIFIC AMINO ACID SEQUENCE | THOMAS JEFFERSON UNIVERSITY | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | ALDH1A1 1079/4885CXCR4 499/4885MEN1 2905/4885 |
| US-20140234217-A1 | REMOTE ASSEMBLY OF TARGETED NANOPARTICLES USING COMPLEMENTARY OLIGONUCLEOTIDE LINKERS | UACA, POLRMT, SDCBP | ALDH1A1 4469/4885CXCR4 871/4885MEN1 1091/4885 |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | EPHA2, ANXA6, SLC10A1 | ALDH1A1 1831/4885CXCR4 175/4885MEN1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.